Aura Biosciences (AURA) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aura Biosciences (AURA) has outperformed Wave Life Sciences (WVE) over the past year, gaining 12.2% versus a loss of 50.8%. Wave Life Sciences is the larger company by market cap ($697.6 million vs $669.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | WVE |
|---|---|---|
| Share price | $6.46 | $3.54 |
| Market cap | $669.93M | $697.55M |
| 1-day change | +4.70% | +0.57% |
| YTD return | +18.53% | -79.18% |
| 1-year return | +12.15% | -50.76% |
| 5-year return | — | -31.26% |
| EPS (TTM) | $-1.75 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $21.73 |
| 52-week low | $4.73 | $3.43 |
| Distance from 52-week high | -32.25% | -83.71% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +156.97% | +410.17% |
| Average volume | 748.04K | 3.10M |
| Shares outstanding | 103.70M | 197.05M |
| Employees | 113 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed WVE by 62.9 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
AURA vs WVE FAQ
Which is bigger, Aura Biosciences or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $697.55M compared with $669.93M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or WVE?
AURA returned +12.15% over the past 12 months, compared with -50.76% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Wave Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Aura Biosciences and Biotechnology: Pharmaceutical Preparations for Wave Life Sciences.